Lazard Asset Management LLC Raises Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Lazard Asset Management LLC raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) by 79.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,887 shares of the company’s stock after buying an additional 3,051 shares during the quarter. Lazard Asset Management LLC’s holdings in iTeos Therapeutics were worth $141,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Texas Permanent School Fund grew its holdings in iTeos Therapeutics by 2.7% in the 2nd quarter. Texas Permanent School Fund now owns 14,642 shares of the company’s stock valued at $302,000 after buying an additional 388 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in iTeos Therapeutics by 282.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 124,797 shares of the company’s stock valued at $2,571,000 after buying an additional 92,192 shares in the last quarter. Integral Health Asset Management LLC grew its holdings in iTeos Therapeutics by 84.2% in the 2nd quarter. Integral Health Asset Management LLC now owns 156,553 shares of the company’s stock valued at $3,225,000 after buying an additional 71,553 shares in the last quarter. Candriam S.C.A. grew its holdings in iTeos Therapeutics by 15.2% in the 2nd quarter. Candriam S.C.A. now owns 787,651 shares of the company’s stock valued at $16,225,000 after buying an additional 103,839 shares in the last quarter. Finally, New York State Teachers Retirement System grew its holdings in iTeos Therapeutics by 249.5% in the 2nd quarter. New York State Teachers Retirement System now owns 21,317 shares of the company’s stock valued at $439,000 after buying an additional 15,217 shares in the last quarter. 94.71% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Stock Up 1.5 %

Shares of iTeos Therapeutics stock opened at $21.24 on Tuesday. iTeos Therapeutics, Inc. has a 52 week low of $16.21 and a 52 week high of $52.43. The business’s fifty day simple moving average is $19.39 and its 200-day simple moving average is $21.01. The firm has a market cap of $755.61 million, a PE ratio of 3.09 and a beta of 1.45.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Further Reading

Institutional Ownership by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.